Find the right fit for you - faster
Get tailored insights about working at Neurotrack in one quick step.
Neurotrack Snapshot
Alzheimer’s, the most common form of dementia, affects more than 50 million people around the world today -- a number that’s expected to double every 20 years, reaching more than 130 million by 2050. It’s a complex disease that, for many, begins in mid-life and manifests in later years, and, at present, has no cure. Neurotrack is building the digital memory health platform of the future, giving people direct access to digital tools and technology to assess, preserve, and strengthen their memory health. Based on 30 years of scientific research, Neurotrack’s comprehensive platform helps people assess their memory through the company’s proprietary ImprintTM cognitive assessment, and manage memory loss and cognitive decline with the help of Neurotrack’s highly personalized digital therapeutic.
We believe in the power of science. It is rooted in all we do. The company regularly invests in studies, partnering with institutions that are leading the field in Alzheimer’s research, like Harvard, Stanford and Brown University, and works with a scientific advisory board comprised of leading academics and clinicians furthering Alzheimer’s and dementia research.
We believe in the power of science. It is rooted in all we do. The company regularly invests in studies, partnering with institutions that are leading the field in Alzheimer’s research, like Harvard, Stanford and Brown University, and works with a scientific advisory board comprised of leading academics and clinicians furthering Alzheimer’s and dementia research.
Neurotrack is an innovative digital health company based in Redwood City, Ca. It has raised more than $50 million in funding from leading venture capital firms including Sozo Ventures, Marc Benioff, Khosla Ventures, Founders Fund, Social Capital, AME Cloud Partners and Rethink Impact, as well as strategic investments from Japanese insurance leaders, Dai-ichi Life and SOMPO Holdings. In 2019, it was the recipient of a SBIR fast-track grant worth up to $3.3 million from the National Institute on Aging, and the company’s scientific co-founders have raised over $7M in NIH grants to conduct research into its underlying technology. It has been named Best Health Company at SXSW, DEMO, and was a participant in the Rock Health accelerator.
Visit us at www.neurotrack.com to learn more.
Visit us at www.neurotrack.com to learn more.
